Fundraising FoxApellis Pharmaceuticals
Unicorn exit · $5.6Bacquired by BiogenCrestwood, US · 11 known investors
Find your way into Apellis Pharmaceuticals
Sign up to find every way you can get introduced to Apellis Pharmaceuticals
- Your email: who you already know at Apellis Pharmaceuticals, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Apellis Pharmaceuticals team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Acquired by Biogen May 2026 · $5.6B ($41 per share cash plus contingent value right up to $4/share, ~$5.6 billion total transaction value) · source ↗
NASDAQ-listed company developing therapies for complement cascade-driven diseases in haematology, ophthalmology, and nephrology.
Founders & leadership
Board
Investors · 11
How we know: Avoro Capital Advisors's portfolio page · Not right? Tell us
How we know: EMBL Ventures's portfolio page · Not right? Tell us
How we know: Epidarex Capital's portfolio page · Not right? Tell us
How we know: F-Prime Capital's portfolio page · Not right? Tell us
How we know: Keyhorse Capital's portfolio page · Not right? Tell us
How we know: Sofinnova Ventures's portfolio page · board seat on SEC Form D · the VCSheet dataset · Not right? Tell us
How we know: venBio Partners's portfolio page · board seat on SEC Form D · the VCSheet dataset · Not right? Tell us
Also in the syndicate · 3
Funding
SEC filings, press & company announcements$134.9M disclosed across 5 of 6 rounds · 2013–2017
- Undisclosed amountSeries CDec 2014
AJU IB Investment Co., Ltd. (lead), Morningside Ventures (lead), Epidarex Ventures
Source ↗
▶$20MraisedAug 2017 · 16 investors · PharmaceuticalsRule 506(b)
- Bihua ChenDirector
- Steven AxonExecutive Officer
- Alec MachielsDirector
- Stephanie O'BrienDirector
- Robert AdelmanDirector
- Nicole PerryExecutive Officer
- Maha KatabiDirector
- Gerald ChanDirector
- A. Sinclair DunlopDirector
- Daniel GeffkenExecutive Officer
- Cedric FrancoisExecutive Officer, Director
- Pascal DeschateletsExecutive Officer
- David WatsonExecutive Officer
- Robert KimExecutive Officer
- Offering amount
- $60.1M
- Amount sold
- $20M
- First sale
- Aug 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$47.1MraisedFeb 2016 · 7 investors · PharmaceuticalsRule 506(b)
- David WatsonExecutive Officer
- Stephanie O'BrienDirector
- Bihua ChenDirector
- Alec MachielsDirector
- Pascal DeschateletsExecutive Officer
- Daniel GeffkenExecutive Officer
- Nicole PerryExecutive Officer
- A. Sinclair DunlopDirector
- Robert AdelmanDirector
- Cedric FrancoisExecutive Officer, Director
- Gerald ChanDirector
- Federico GrossiExecutive Officer
- Offering amount
- $47.1M
- Amount sold
- $47.1M
- First sale
- Dec 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$32.1MraisedJan 2016 · 6 investors · PharmaceuticalsRule 506(b)
- Cedric FrancoisExecutive Officer, Director
- A. Sinclair DunlopDirector
- Bihua ChenDirector
- Pascal DeschateletsExecutive Officer
- Federico GrossiExecutive Officer
- Daniel GeffkenExecutive Officer
- David WatsonExecutive Officer
- Stephanie O'BrienDirector
- Nicole PerryExecutive Officer
- Gerald ChanDirector
- Alec MachielsDirector
- Offering amount
- $32.1M
- Amount sold
- $32.1M
- First sale
- Dec 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$17.7MraisedJun 2015 · 1 investors · BiotechnologyRule 506(b)
- Gerald ChanDirector
- Stephanie O'BrienDirector
- Alec MachielsDirector
- A. Sinclair DunlopDirector
- Pascal DeschateletsExecutive Officer
- Cedric FrancoisExecutive Officer, Director
- Offering amount
- $17.7M
- Amount sold
- $17.7M
- Minimum investment
- $10K
- First sale
- Dec 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$17.8MraisedAug 2014 · 25 investors · PharmaceuticalsRule 506(b)
- Alec MachielsDirector
- Stephanie O'BrienDirector
- Cedric FrancoisExecutive Officer, Director
- Gerald ChanDirector
- Pascal DeschateletsExecutive Officer
- Offering amount
- $24M
- Amount sold
- $17.8M
- First sale
- Jul 2013
- Incorporated
- Corporation, Delaware, 2009
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
3 people who came through Apellis Pharmaceuticals went on to found or lead other companies.
In the news
Frequently asked questions
- What does Apellis Pharmaceuticals do?
- NASDAQ-listed company developing therapies for complement cascade-driven diseases in haematology, ophthalmology, and nephrology.
- Who are Apellis Pharmaceuticals's investors?
- Apellis Pharmaceuticals's investors include Avoro Capital Advisors, EMBL Ventures, Epidarex Capital, F-Prime Capital, Keyhorse Capital, Sofinnova Ventures, Solasta Ventures, venBio Partners.
- How much funding has Apellis Pharmaceuticals raised?
- Apellis Pharmaceuticals has disclosed $134.9M raised across 5 of its 6 known rounds.
- Who acquired Apellis Pharmaceuticals?
- Apellis Pharmaceuticals was acquired by Biogen.
- Where is Apellis Pharmaceuticals headquartered?
- Apellis Pharmaceuticals is headquartered in Crestwood, US.